Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vistagen Therapeutics Inc's Business Segments
Vistagen Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
License
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License13.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | 13.6% |
Annual Results
Revenue Share by Reportable Segment - FY
- License13.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | 13.6% |
Description of Vistagen Therapeutics Inc
Vistagen Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of new medications for mental health disorders. The company is headquartered in South San Francisco, California, and was founded in 1998.
Vistagen Therapeutics uses its proprietary drug platform, the NeuroStart Technology, to discover and develop new treatment options for various central nervous system (CNS) conditions. Their technology focuses on identifying and targeting specific receptors in the brain that are associated with mental health disorders such as anxiety, depression, and other mood-related conditions.
The company's lead product candidate is AV-101, which is being developed for major depressive disorder (MDD) and suicidal ideation. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which has the potential to restore normal glutamatergic signaling in the brain. The drug works by selectively modulating the N-methyl-D-aspartate (NMDA) receptor, an important target for the treatment of depression.
Vistagen Therapeutics has conducted multiple clinical trials to evaluate the safety and efficacy of AV-101. These trials have shown promising results, with AV-101 demonstrating potential as a novel treatment for MDD and other CNS disorders. The company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for development of AV-101 for the adjunctive treatment of MDD.
In addition to AV-101, Vistagen Therapeutics also has other product candidates in its pipeline. One of them is PH94B, a neuroactive steroid nasal spray being developed for the treatment of social anxiety disorder (SAD). PH94B is designed to provide rapid-onset and short-duration anxiety relief, making it suitable for situational use.
Another notable product candidate is PH10, which is being developed as an acute treatment for MDD. PH10 is a synthetic neurosteroid nasal spray that works by activating nasal chemosensory neurons to trigger neural circuits in the brain that regulate mood.
Vistagen Therapeutics has a strong focus on improving the lives of individuals suffering from mental health disorders. Their efforts are guided by a combination of scientific research, clinical trial data, and strategic partnerships with leading academic institutions and pharmaceutical companies.
Overall, Vistagen Therapeutics Inc is a biopharmaceutical company at the forefront of developing new treatment options for mental health disorders. Their pipeline of innovative product candidates holds significant potential in addressing the unmet medical needs of patients with conditions such as major depressive disorder, social anxiety disorder, and other CNS disorders.
Vistagen Therapeutics uses its proprietary drug platform, the NeuroStart Technology, to discover and develop new treatment options for various central nervous system (CNS) conditions. Their technology focuses on identifying and targeting specific receptors in the brain that are associated with mental health disorders such as anxiety, depression, and other mood-related conditions.
The company's lead product candidate is AV-101, which is being developed for major depressive disorder (MDD) and suicidal ideation. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which has the potential to restore normal glutamatergic signaling in the brain. The drug works by selectively modulating the N-methyl-D-aspartate (NMDA) receptor, an important target for the treatment of depression.
Vistagen Therapeutics has conducted multiple clinical trials to evaluate the safety and efficacy of AV-101. These trials have shown promising results, with AV-101 demonstrating potential as a novel treatment for MDD and other CNS disorders. The company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for development of AV-101 for the adjunctive treatment of MDD.
In addition to AV-101, Vistagen Therapeutics also has other product candidates in its pipeline. One of them is PH94B, a neuroactive steroid nasal spray being developed for the treatment of social anxiety disorder (SAD). PH94B is designed to provide rapid-onset and short-duration anxiety relief, making it suitable for situational use.
Another notable product candidate is PH10, which is being developed as an acute treatment for MDD. PH10 is a synthetic neurosteroid nasal spray that works by activating nasal chemosensory neurons to trigger neural circuits in the brain that regulate mood.
Vistagen Therapeutics has a strong focus on improving the lives of individuals suffering from mental health disorders. Their efforts are guided by a combination of scientific research, clinical trial data, and strategic partnerships with leading academic institutions and pharmaceutical companies.
Overall, Vistagen Therapeutics Inc is a biopharmaceutical company at the forefront of developing new treatment options for mental health disorders. Their pipeline of innovative product candidates holds significant potential in addressing the unmet medical needs of patients with conditions such as major depressive disorder, social anxiety disorder, and other CNS disorders.
VistaGen Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for nerve-center-driven diseases, particularly in the areas of depression, anxiety, and other central nervous system disorders. Below is an extensive overview of the segments, products, and services offered by the company.
Segments
1. Drug Development for Anxiety and Depression:
VistaGen is primarily recognized for its innovative approach in developing therapies that target anxiety and depression. This includes research focused on improving treatment outcomes for individuals who do not adequately respond to traditional therapies.
2. Central Nervous System (CNS) Therapeutics:
The company emphasizes a broader spectrum of CNS disorders, seeking to address unmet medical needs in this area. Their research potentially includes conditions like post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and other stress-related disorders.
3. Preclinical and Clinical Development:
VistaGen engages in both preclinical and clinical development phases. The company’s research pipeline includes novel compounds that have completed various stages of clinical trials and other candidates still in preclinical development phases.
Products
1. AV-101 (5-Hydroxytryptophan or 5-HTP):
AV-101 is a core product of VistaGen, designed as a novel, non-opioid therapeutic for the treatment of depression and PTSD. It aims to enhance the safety and efficacy profile compared to current standard treatments by targeting different biochemical pathways within the brain.
2. PH94B:
PH94B is a nasal spray that VistaGen is developing for the treatment of social anxiety disorder. It acts rapidly and is aimed at providing relief of acute anxiety symptoms, offering an alternative route of administration that is expected to facilitate quicker onset of action.
3. PH10:
Another promising product candidate, PH10, is designed for the treatment of major depressive disorder. Similar to PH94B, PH10 is also delivered intranasally and is intended to provide a quick-acting solution to manage depressive symptoms, with a focus on reducing the burden of side effects commonly associated with traditional antidepressants.
4. Other Pipeline Candidates:
VistaGen maintains an active pipeline of potential drugs in various stages of development, including preclinical initiatives aimed at identifying new therapeutic candidates that target additional CNS disorders.
Services
1. Clinical Trial Management:
VistaGen undertakes extensive clinical trial management functions, ranging from the design and implementation of clinical studies to the analysis and reporting of clinical trial data. This involves collaboration with clinical research organizations (CROs) to ensure compliance with regulatory standards.
2. Research Collaborations:
The company is open to strategic collaborations and partnerships with academic institutions, other biotech firms, and pharmaceutical companies to advance its drug development initiatives. These partnerships often enhance research capabilities and broaden the scope of clinical studies.
3. Intellectual Property Management:
VistaGen places a strong emphasis on protecting its proprietary technologies and compounds through patents and other intellectual property mechanisms. This includes ongoing efforts to secure patent protection for new candidates and innovative drug delivery systems that enhance therapeutic use.
4. Regulatory Affairs:
The company is engaged in navigating the complex regulatory landscape required for drug approval. This involves interaction with the Food and Drug Administration (FDA) and other regulatory bodies to gain necessary approvals for clinical trials and eventual market entry of its products.
In summary, VistaGen Therapeutics Inc. operates primarily within the CNS therapeutic segment, focusing on innovative treatments for anxiety and depression through a pipeline of novel drug candidates. The company provides a suite of services that supports clinical development, regulatory affairs, and research collaborations, positioning itself as a key player in addressing unmet needs in mental health therapies.
Segments
1. Drug Development for Anxiety and Depression:
VistaGen is primarily recognized for its innovative approach in developing therapies that target anxiety and depression. This includes research focused on improving treatment outcomes for individuals who do not adequately respond to traditional therapies.
2. Central Nervous System (CNS) Therapeutics:
The company emphasizes a broader spectrum of CNS disorders, seeking to address unmet medical needs in this area. Their research potentially includes conditions like post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and other stress-related disorders.
3. Preclinical and Clinical Development:
VistaGen engages in both preclinical and clinical development phases. The company’s research pipeline includes novel compounds that have completed various stages of clinical trials and other candidates still in preclinical development phases.
Products
1. AV-101 (5-Hydroxytryptophan or 5-HTP):
AV-101 is a core product of VistaGen, designed as a novel, non-opioid therapeutic for the treatment of depression and PTSD. It aims to enhance the safety and efficacy profile compared to current standard treatments by targeting different biochemical pathways within the brain.
2. PH94B:
PH94B is a nasal spray that VistaGen is developing for the treatment of social anxiety disorder. It acts rapidly and is aimed at providing relief of acute anxiety symptoms, offering an alternative route of administration that is expected to facilitate quicker onset of action.
3. PH10:
Another promising product candidate, PH10, is designed for the treatment of major depressive disorder. Similar to PH94B, PH10 is also delivered intranasally and is intended to provide a quick-acting solution to manage depressive symptoms, with a focus on reducing the burden of side effects commonly associated with traditional antidepressants.
4. Other Pipeline Candidates:
VistaGen maintains an active pipeline of potential drugs in various stages of development, including preclinical initiatives aimed at identifying new therapeutic candidates that target additional CNS disorders.
Services
1. Clinical Trial Management:
VistaGen undertakes extensive clinical trial management functions, ranging from the design and implementation of clinical studies to the analysis and reporting of clinical trial data. This involves collaboration with clinical research organizations (CROs) to ensure compliance with regulatory standards.
2. Research Collaborations:
The company is open to strategic collaborations and partnerships with academic institutions, other biotech firms, and pharmaceutical companies to advance its drug development initiatives. These partnerships often enhance research capabilities and broaden the scope of clinical studies.
3. Intellectual Property Management:
VistaGen places a strong emphasis on protecting its proprietary technologies and compounds through patents and other intellectual property mechanisms. This includes ongoing efforts to secure patent protection for new candidates and innovative drug delivery systems that enhance therapeutic use.
4. Regulatory Affairs:
The company is engaged in navigating the complex regulatory landscape required for drug approval. This involves interaction with the Food and Drug Administration (FDA) and other regulatory bodies to gain necessary approvals for clinical trials and eventual market entry of its products.
In summary, VistaGen Therapeutics Inc. operates primarily within the CNS therapeutic segment, focusing on innovative treatments for anxiety and depression through a pipeline of novel drug candidates. The company provides a suite of services that supports clinical development, regulatory affairs, and research collaborations, positioning itself as a key player in addressing unmet needs in mental health therapies.